Ontology highlight
ABSTRACT: Background
Management of moderate-to-severe atopic dermatitis (AD) commonly requires long-term treatment.Objective
The aim of this study was to report the safety and efficacy of dupilumab treatment for up to 3 years in adults with moderate-to-severe AD.Methods
This ongoing, multicenter, open-label extension study (LIBERTY AD OLE; NCT01949311) assessed dupilumab treatment in adults previously enrolled in dupilumab trials. Patients received dupilumab 300 mg weekly up to 148 weeks. The primary outcome was safety.Results
Of 2677 patients enrolled and treated, 347 reached week 148. Mean self-reported drug compliance was 98.2%. Safety data were consistent with previously reported trials (270.1 adverse events [AEs]/100 patient-years; 6.9 serious AEs/100 patient-yea
SUBMITTER: Beck LA
PROVIDER: S-EPMC7371647 | biostudies-literature | 2020 Aug
REPOSITORIES: biostudies-literature